Race reveals new strategy for cancer drug Bisantrene
Filed with ASX · · 27 pages · English
The strategy defines five paths for the clinical development of Bisantrene that greatly expands the addressable market for Bisantrene while reducing clinical development risk and targeting cancers beyond Acute Myeloid Leukaemia (AML). The new strategy builds on the value embedded in Bisantrene from its use in more than 40 prior human trials across a range of cancers. Race Oncology will continue to
Earlier from Racura Oncology
- Appendix 4C - quarterly
- Prominent biotech investor leads investment in Race
- First patient treated in Bisantrene trial in Israel
- Bisantrene AML trial to start in Israel
- Bisantrene IND Update
Later from Racura Oncology
- Race Receives $159k R&D Tax Incentive Refund
- December 2019 Quarterly Report
- Race Secures A$1.8m strategic placement
- Race starts preclinical breast cancer study for Bisantrene
- Managing Director Resignation
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology